Plasma cystatin c concentration reflects the severity of coronary artery disease in patients without chronic kidney disease

Circulation Journal

Volumn 74, Issue 11, 2010, Pages 2441-2447

  Kiyosue, Arihiro ^a   Hirata, Yasunobu ^a   Ando, Jiro ^a   Fujita, Hideo ^a   Morita, Toshihiro ^a   Takahashi, Masao ^a   Nagata, Daisuke ^a   Kohro, Takahide ^a   Imai, Yasushi ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic kidney disease; Coronary artery disease; Glomerular filtration rate; Renal function

Indexed keywords

CREATININE; CYSTATIN C;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REFERENCE VALUE; RISK ASSESSMENT;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOENZYME TECHNIQUES; JAPAN; KIDNEY DISEASES; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 78349234263     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0158     Document Type: Article

References (37)

1. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998; 11: 239-245.
2. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615.
3. Schrier RW. Role of diminished renal function in cardiovascular mortality: Marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1-8.
4. Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
6. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.
7. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172-180.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-470.
9. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem 1992; 38: 1933-1953.
10. Kassirer JP. Clinical evaluation of kidney function--tubular function. N Engl J Med 1971; 285: 499-502.
11. Kassirer JP. Clinical evaluation of kidney function--glomerular function. N Engl J Med 1971; 285: 385-389.
12. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
13. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
15. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51: 5-40.
16. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: Efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 2000; 20: 97-102.
17. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
18. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman- Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246.
19. Wang J, Sim AS, Wang XL, Salonikas C, Moriatis M, Naidoo D, et al. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis 2008; 197: 853-859.
20. Sekizuka H, Akashi YJ, Kawasaki K, Yamauchi M, Musha H. Cystatin C: A better marker to detect coronary artery sclerosis. J Cardiol 2009; 54: 359-367.
21. Ichimoto E, Jo K, Kobayashi Y, Inoue T, Nakamura Y, Kuroda N, et al. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J 2009; 73: 1669-1673.
22. Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J 2008; 72: 1499-1505.
23. Curhan G. Cystatin C: A marker of renal function or something more? Clin Chem 2005; 51: 293-294.
24. Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003; 63: 1944-1947.
25. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001; 47: 2055-2059.
26. Kos J, Stabuc B, Cimerman N, Brünner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998; 44: 2556-2557.
27. Chuo LJ, Sheu WH, Pai MC, Kuo YM. Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Dement Geriatr Cogn Disord 2007; 23: 251-257.
28. Collé A, Tavera C, Prévot D, Leung-Tack J, Thomas Y, Manuel Y, et al. Cystatin C levels in sera of patients with human immunodeficiency virus infection: A new avidin-biotin ELISA assay for its measurement. J Immunoassay 1992; 13: 47-60.
29. Séronie-Vivien S, Delanaye P, Piéroni L, Mariat C, Froissart M, Cristol JP, et al. Cystatin C: Current position and future prospects. Clin Chem Lab Med 2008; 46: 1664-1686.
30. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-1197.
31. Bengtsson E, To F, Håkansson K, Grubb A, Brånén L, Nilsson J, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 2151-2156.
32. Sukhova GK, Wang B, Libby P, Pan JH, Zhang Y, Grubb A, et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 2005; 96: 368-375.
33. Niccoli G, Conte M, Della Bona R, Altamura L, Siviglia M, Dato I, et al. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis 2008; 198: 373-380.
34. Hirata Y, Matsumoto A, Aoyagi T, Yamaoki K, Komuro I, Suzuki T, et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001; 51: 585-591.
35. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 55-60.
36. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983; 71: 1854-1866.
37. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.